Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease

The aim of this study was to evaluate the combination of intralesional verapamil injection (IVI) therapy with and tadalafil in men affected by Peyronie's disease (PD).

In this study, 59 patients diagnosed with PD, were divided into three groups.

Group A (GA) counted 23 patients treated with IVI; Group B (GB) treated 19 patients with tadalafil 5 mg once a day, and Group C (GC) treated 17 patients with IVI and tadalafil for 3 months. There were assessed at baseline and follow-up: Erectile function, presence and severity of painful erections, penile plaque size and penile curvature degree.

After 3 months pain resolved completely in 57% cases of GA, 61% of GB and 76% of GC; the final mean curvature degree further decreased in all groups without statistically significant differences; mean plaque size remained stable in GA: 1. 57 versus 1. 59 at baseline (P = 0. 364) and GB: 1. 51 versus 1. 52 at baseline (P = 0,265), while a further decrease was evident in GC: 1. 46 versus 1. 58 at baseline (P = 0. 03). Mean International Index of Erectile Function-5 score further improved significantly in the group treated with verapamil plus tadalafil: 23. 1 versus 14. 4 of GA and 18. 2 of GB (P ≤ 0. 01).

The association of IVI and tadalafil showed better pain control while reducing penile curvature and erectile function, improving the quality of life.

Urology annals. 0000 [Epub]

Lucio Dell'Atti

Department of Urology, University Hospital S. Anna, Ferrara, Italy.

PubMed      Full Text Article

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe